Vorma Home Hero

Vor Bio
Medical Affairs

We are dedicated to advancing science to help patients living with autoimmune diseases and support clinical advancements. Our mission drives the work we do every day.

Our Areas of Focus

Myasthenia Gravis (MG)

Mg Hero Image Aspect Ratio 730 468

Sjögren’s 
Disease (SjD)

Sj Hero Image Aspect Ratio 730 468

Upcoming Medical Congress Events

View All Events

Our Latest Publications

European Academy of Neurology (EAN 2026)

Geneva, Switzerland
|
2026

A Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis: Trial Design Update

Congress of Clinical Rheumatology – East (CCR East 2026)

Destin, FL
|
2026

Telitacicept as a Novel BAFF/APRIL-Targeted Therapy for Sjögren’s Disease

American Academy of Neurology (AAN 2026)

Chicago, IL
|
2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (UPSTREAM MG)

Carrell-Krusen Neuromuscular Symposium (CK 2026)

Dallas, TX
|
2026

Global Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (RemeMG)

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2025)

San Francisco, CA
|
2025

Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study

American College of Rheumatology (ACR 2025)

Chicago, IL
|
2025

Efficacy and safety of telitacicept in participants with Sjögren’s disease: Results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study

View All Publications

Have a question? Submit a Medical Information Request.

Learn More